Introduction: Nitrosamine Risk Assessment in Generic Drugs is now a key scientific process used to control harmful impurities in medicines. […]
Nitrosamine Risk Assessment in Generic Drug Development for ANDA Submission Read More »
Introduction: Quantification Methods in E&L Testing play a crucial role in determining the safety of pharmaceutical products, medical devices, and
Quantifying Leachables: Relative vs Absolute Quantification Read More »
Introduction The comparison of Peptide vs Antibody Oligonucleotide Conjugates has become an important topic in the development of modern oligonucleotide
Comparison of POCs vs Antibody-Oligonucleotide Conjugates Read More »
Introduction: The primary therapeutic advantage of Peptide Oligonucleotide Conjugates Drug Delivery lies in its ability to enable precise, extrahepatic tissue
Drug Delivery Advantages of Peptide-Oligonucleotide Conjugates (POCs) Read More »
Introduction Peptide Oligonucleotide Conjugates Pharmacokinetics focuses on how peptide-linked nucleic acid therapeutics distribute, metabolize, and remain active in biological systems
Pharmacokinetics of Peptide-Oligonucleotide Conjugates Read More »
Introduction: Exaggerated vs Simulated Extraction E&L is one of the most frequently misunderstood topics in extractables and leachables studies. Many
Exaggerated vs Simulated Use Extractions: What’s the Difference? Read More »
Introduction: Peptide-oligonucleotide conjugates (POCs) require carefully controlled strategies to remain stable because they combine two sensitive components—peptides and nucleic acids.
Stability Considerations for Peptide-Oligonucleotide Conjugates Read More »
Introduction: E&L Sample Preparation Best Practices play a crucial role in ensuring reliable results in extractables and leachables testing. Even
Best Practices for Sample Preparation in E&L Testing Read More »
Introduction Forced Degradation Studies for ANDA play an important role in stability assessment and impurity control during generic drug development.
Forced Degradation Studies for ANDA: Designing Stability and Impurity Pathways Read More »
Introduction In Abbreviated New Drug Applications (ANDA), ANDA Analytical Deficiencies are one of the most common reasons for delays, Complete
Common Analytical Deficiencies in ANDA Submissions (and How to Avoid Them) Read More »
